SOLV on NYSE

Solventum

Logo: Solventum, Public domain, via Wikimedia Commons⁵

American health care company

Solventum Corporation is an American health care company that was spun off from 3M on April 1, 2024.³ It employed about 20,000 people in 2025.¹ Its revenue was $8.3 billion in 2025.¹ Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

Apr 1, 2024Founded¹

Compare with Baxter International, ResMed or Dexcom, or pick any stock.

TickerSOLV on NYSE¹
Industryhealth care, health information technology, medical technology industry¹
HeadquartersEagan¹
Founded inDelaware¹
Websitewww.solventum.com
Legal formcorporation¹
Incorporated inDE⁶
Business address1750 Yankee Doodle Road, Eagan, Mn 55121⁶
Filer categoryLarge accelerated filer⁶
LEI254900I70403OSGY4M28⁴
StatusActive⁴
LEI statusIssued and current⁴
Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States⁴
Registered withDivision of Corporations, Department of State, 7253837⁴

See how the biggest companies compare on our leaderboards

Solventum Corporation is an American health care company that was spun off from 3M on April 1, 2024.³

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

53.5%Gross margin⁹

26.2%Operating margin⁹

18.7%Net margin⁹

0.9%Revenue growth, 2025⁹

30.8%Return on equity⁹

1.00×Debt to equity⁹

-$10.0MFree cash flow⁹

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 76% of the revenue Solventum broke down this way in fiscal 2025.

Product$6.3B⁹76%up 0% from 2024
Cost Of Software And Rentals$2.0B⁹24%up 4% from 2024

Products and services by year

Products and services	2023	2024	2025
Product	$6.3B	$6.3B	$6.3B
Cost Of Software And Rentals	$1.9B	$1.9B	$2.0B

Business segments

MedSurg brought in 60% of the revenue Solventum broke down this way in fiscal 2025.

MedSurg$4.8B⁹60%up 4% from 2024
Health Information Systems$1.4B⁹17%up 4% from 2024
Dental Solutions$1.3B⁹17%up 4% from 2024
Purification and Filtration$497.0M⁹6%down 30% from 2024

Business segments by year

Business segments	2023	2024	2025
MedSurg	$4.6B	$4.6B	$4.8B
Health Information Systems	$1.3B	$1.3B	$1.4B
Dental Solutions	$1.3B	$1.3B	$1.3B
Purification and Filtration	$689.0M	$709.0M	$497.0M

Regions

United States brought in 56% of the revenue Solventum broke down this way in fiscal 2025.

United States$4.7B⁹56%up 2% from 2024
Outside the United States$3.7B⁹44%down 1% from 2024

Regions by year

Regions	2023	2024	2025
United States	$4.5B	$4.6B	$4.7B
Outside the United States	$3.7B	$3.7B	$3.7B

Where the money goes

Where each dollar of revenue went, fiscal 2025

Selling, general and adminOther costsProfit

Research and development9¢$739.0M
Selling, general and admin37¢$3.1B
Other costs34¢$2.8B
Income tax2¢$157.0M
Profit19¢$1.6B

Out of $8.3B in revenue.⁹

Where each dollar of operating cash went, fiscal 2025

Capital spending

Capital spending100¢$379.0M

Out of $369.0M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.⁹

Financial statements

Revenue¹⁰⁹$8.3B in 2025+2% since 2022

Gross profit¹⁰⁹$4.5B in 2025−5% since 2022

Operating income¹⁰⁹$2.2B in 2025+29% since 2022

Net income¹⁰⁹$1.6B in 2025+16% since 2022

Every line of the income statement as filed: the last 3 fiscal years, latest first.⁹

Period ending	2025-12-31	2024-12-31	2023-12-31
Total net sales	$8.3B	$8.3B	$8.2B
Gross profit	$4.5B	$4.6B	$4.7B
Selling, general and administrative expenses	$3.1B	$2.8B	$2.3B
Research and development expenses	$739.0M	$775.0M	$758.0M
Gain on sale of business	-$1.5B	$0	-$56.0M
Operating income	$2.2B	$1.0B	$1.7B
Interest expense, net	$347.0M	$367.0M	$0
Loss on debt extinguishment, net	$82.0M	$0	$0
Other expense (income), net	$39.0M	$64.0M	$25.0M
Income before income taxes	$1.7B	$605.0M	$1.7B
Provision for income taxes	$157.0M	$127.0M	$321.0M
Net income	$1.6B	$479.0M	$1.3B
Basic earnings per share (in dollars per share)	$8.94	$2.77	$7.79
Diluted earnings per share (in dollars per share)	$8.88	$2.76	$7.79
Basic (in shares)	174.1M shares	173.2M shares	172.7M shares
Diluted (in shares)	175.3M shares	173.7M shares	172.7M shares

Total assets¹⁰⁹$14.3B in 2025+3% since 2023

Total liabilities¹⁰⁹$9.2B in 2025+306% since 2023

Shareholders’ equity¹⁰⁹$5.0B in 2025−58% since 2021

Cash¹⁰⁹$878.0M in 2025+865% since 2021

Long-term debt¹⁰⁹$5.0B in 2025

Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 5 quarters (quarterly), latest first.⁹

Period ending	2025-12-31	2024-12-31	2024-03-31	2023-12-31	2022-12-31
Cash and cash equivalents	$878.0M	$762.0M
Accounts receivable net of allowances of $87 and $86	$1.0B	$1.0B
Due from related parties	$150.0M	$185.0M
Finished goods	$636.0M	$539.0M
Work in process	$201.0M	$190.0M
Raw materials and supplies	$229.0M	$236.0M
Total inventories	$1.1B	$965.0M
Other current assets	$731.0M	$293.0M
Total current assets	$3.9B	$3.2B
Property, plant and equipment net	$1.3B	$1.6B
Goodwill	$5.7B	$6.4B		$6.5B
Intangible assets net	$2.6B	$2.5B
Other assets	$814.0M	$665.0M
Total assets	$14.3B	$14.5B
Short-term borrowings and current portion of long-term debt	$0	$200.0M
Accounts payable	$687.0M	$618.0M
Due to related parties	$435.0M	$272.0M
Unearned revenue	$621.0M	$572.0M
Other current liabilities	$1.4B	$1.0B
Total current liabilities	$3.1B	$2.7B
Long-term debt	$5.0B	$7.8B
Pension and postretirement benefits	$363.0M	$350.0M
Deferred income taxes	$164.0M	$225.0M
Other liabilities	$547.0M	$410.0M
Total liabilities	$9.2B	$11.5B
Common stock, par value $0.01 per share, 750,000,000 shares authorized	$2.0M	$2.0M
Additional paid-in-capital	$3.9B	$3.8B
Retained earnings	$1.8B	$242.0M
Accumulated other comprehensive income (loss)	-$625.0M	-$1.1B
Total equity	$5.0B	$3.0B		$11.7B	$11.7B
Total liabilities and equity	$14.3B	$14.5B
Allowance for credit loss	$87.0M	$86.0M
Common stock par value (in dollars per share)	$0.01	$0.01
Common stock authorized (in shares)	750.0M shares	750.0M shares
Common stock issued (in shares)	173.5M shares	172.8M shares	0 shares
Common stock outstanding (in shares)	173.5M shares	172.8M shares	0 shares

Period ending	2025-12-31	2024-12-31	2024-03-31	2023-12-31	2022-12-31
Cash and cash equivalents	$878.0M	$762.0M
Accounts receivable net of allowances of $87 and $86	$1.0B	$1.0B
Due from related parties	$150.0M	$185.0M
Finished goods	$636.0M	$539.0M
Work in process	$201.0M	$190.0M
Raw materials and supplies	$229.0M	$236.0M
Total inventories	$1.1B	$965.0M
Other current assets	$731.0M	$293.0M
Total current assets	$3.9B	$3.2B
Property, plant and equipment net	$1.3B	$1.6B
Goodwill	$5.7B	$6.4B		$6.5B
Intangible assets net	$2.6B	$2.5B
Other assets	$814.0M	$665.0M
Total assets	$14.3B	$14.5B
Short-term borrowings and current portion of long-term debt	$0	$200.0M
Accounts payable	$687.0M	$618.0M
Due to related parties	$435.0M	$272.0M
Unearned revenue	$621.0M	$572.0M
Other current liabilities	$1.4B	$1.0B
Total current liabilities	$3.1B	$2.7B
Long-term debt	$5.0B	$7.8B
Pension and postretirement benefits	$363.0M	$350.0M
Deferred income taxes	$164.0M	$225.0M
Other liabilities	$547.0M	$410.0M
Total liabilities	$9.2B	$11.5B
Common stock, par value $0.01 per share, 750,000,000 shares authorized	$2.0M	$2.0M
Additional paid-in-capital	$3.9B	$3.8B
Retained earnings	$1.8B	$242.0M
Accumulated other comprehensive income (loss)	-$625.0M	-$1.1B
Total equity	$5.0B	$3.0B		$11.7B	$11.7B
Total liabilities and equity	$14.3B	$14.5B
Allowance for credit loss	$87.0M	$86.0M
Common stock par value (in dollars per share)	$0.01	$0.01
Common stock authorized (in shares)	750.0M shares	750.0M shares
Common stock issued (in shares)	173.5M shares	172.8M shares	0 shares
Common stock outstanding (in shares)	173.5M shares	172.8M shares	0 shares

Cash from operations¹⁰⁹$369.0M in 2025−78% since 2022

Capital spending¹⁰⁹$379.0M in 2025+51% since 2022

Free cash flow¹⁰⁹-$10.0M in 2025

Every line of the cash flow as filed: the last 3 fiscal years, latest first.⁹

Period ending	2025-12-31	2024-12-31	2023-12-31
Net income	$1.6B	$479.0M	$1.3B
Depreciation and amortization	$489.0M	$555.0M	$561.0M
Pension and postretirement benefit expense	$62.0M	$34.0M	$41.0M
Stock-based compensation expense	$161.0M	$112.0M	$39.0M
Gain on sale of business	-$1.5B	$0	-$56.0M
Transaction costs	-$111.0M	$0	$0
Deferred income taxes	-$120.0M	-$155.0M	-$142.0M
Accounts receivable	$34.0M	$43.0M	-$129.0M
Due from related parties	$44.0M	$233.0M	$0
Inventories	-$139.0M	-$132.0M	$23.0M
Accounts payable	$104.0M	$266.0M	$105.0M
Due to related parties	-$11.0M	-$395.0M	$0
Accrued compensation	$43.0M	$78.0M	$142.0M
All other operating activities - net	-$194.0M	$67.0M	-$15.0M
Net cash provided by operating activities	$369.0M	$1.2B	$1.9B
Purchases of property, plant and equipment	-$379.0M	-$380.0M	-$290.0M
Acquisitions, net of cash acquired	-$696.0M	$0	$0
Proceeds from sale of business	$3.9B	$0	$60.0M
Other net	-$18.0M	$0	$0
Net cash provided by (used in) investing activities	$2.8B	-$380.0M	-$230.0M
Repayment of debt	-$3.1B	-$300.0M	$0
Net transfers to 3M	-$33.0M	-$8.3B	-$1.6B
Proceeds from long-term debt, net of issuance costs	$0	$8.3B	$0
Other net	$46.0M	$8.0M	$1.0M
Net cash used in financing activities	-$3.1B	-$240.0M	-$1.6B
Effect of exchange rate changes on cash and cash equivalents	$7.0M	$3.0M	$0
Net increase (decrease) in cash and cash equivalents	$116.0M	$568.0M	$133.0M
Income taxes	$181.0M	$244.0M	$0
Interest	$442.0M	$287.0M	$0

Compare Solventum with another company

Corporate structure

Solventum sits at the top of its group. 81 entities, 40 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Solventum

VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on Solventum, latest Apr 30, 2026
VANGUARD GROUP INC Filed SCHEDULE 13G/A on Solventum, latest Mar 27, 2026 (3 filings since Nov 4, 2024)
Independent Franchise Partners LLP Filed SCHEDULE 13G/A on Solventum, latest Jan 27, 2026 (3 filings since Aug 13, 2025)
3M Filed SCHEDULE 13G/A on Solventum, latest Aug 18, 2025 (2 filings since Nov 14, 2024)
BlackRock Filed SC 13G on Solventum, latest Nov 8, 2024 (2 filings since Oct 24, 2024)

Solventum Maplewood, Minnesota, United States
- 3M Healthcare (Shanghai) Co. Ltd. Subsidiary · China
- 3M Healthcare Canada Company Limited Subsidiary · Canada
- 3M Healthcare EMEA Export Limited Subsidiary · Ireland
- 3M Medical Devices and Materials Manufacturing (Shanghai) Co., Ltd. Subsidiary · China
- Crawford Healthcare Canada Limited Subsidiary · Canada
- Crawford Healthcare Holdings Limited Subsidiary · United Kingdom
- Crawford Healthcare Limited Subsidiary · United Kingdom
- Derms Development Limited Subsidiary · United Kingdom
- KCI APAC Holding Ltd Subsidiary · Cayman Islands
- KCI Austria GmbH Subsidiary · Austria
- KCI Brasil Importadora E Distribuidora De Produtos Para Saude Ltda. Subsidiary · Brazil
- KCI Cayman Holdings Subsidiary · Cayman Islands
- KCI Cayman Holdings II Subsidiary · Cayman Islands
- KCI Clinic Spain, S.L.U. Subsidiary · Spain
- KCI Colombia SAS Subsidiary · Colombia
- KCI Europe Holding B.V. Subsidiary · Netherlands
- KCI Hong Kong Holding Limited Subsidiary · Hong Kong
- KCI KK Subsidiary · Japan
- KCI Manufacturing Unlimited Company Subsidiary · Ireland
- KCI Medical (China) Co., Ltd. Subsidiary · China
- KCI Medical AB Subsidiary · Sweden
- KCI Medical Aps Subsidiary · Denmark
- KCI Medical Asia Pte. Ltd. Subsidiary · Singapore
- KCI Medical Australia Pty Ltd Subsidiary · Australia
- KCI Medical Belgium BVBA Subsidiary · Belgium
- and 55 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Solventum reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Item	Latest	A year before	Change
Property and equipment, before depreciation	$3.2B⁹ Dec 31, 2025	$3.6B⁹ Dec 31, 2024	−11.6%
Accumulated depreciation	$1.9B⁹ Dec 31, 2025	$2.0B⁹ Dec 31, 2024	−6.1%
Property and equipment, net	$1.3B⁹ Dec 31, 2025	$1.6B⁹ Dec 31, 2024	−18.2%
Operating-lease assets (leased space)	$214.0M⁹ Dec 31, 2025	$176.0M⁹ Dec 31, 2024	+21.6%

Investments

Item	Latest	A year before	Change
Cash and cash equivalents	$878.0M⁹ Dec 31, 2025	$762.0M⁹ Dec 31, 2024	+15.2%

Intangibles and goodwill

Item	Latest	A year before	Change
Goodwill	$5.7B⁹ Dec 31, 2025	$6.4B⁹ Dec 31, 2024	−10.6%
Intangible assets, net (excluding goodwill)	$2.6B⁹ Dec 31, 2025	$2.5B⁹ Dec 31, 2024	+1.9%
Indefinite-lived intangibles (excluding goodwill)	$0¹⁰ Dec 31, 2024	$25.0M¹⁰ Dec 31, 2023	−100.0%
Finite-lived intangibles, gross	$4.8B⁹ Dec 31, 2025	$5.3B⁹ Dec 31, 2024	−10.5%
Accumulated amortization	$2.2B⁹ Dec 31, 2025	$2.8B⁹ Dec 31, 2024	−21.7%
Finite-lived intangibles, net	$2.5B¹⁰ Dec 31, 2024	$2.9B¹⁰ Dec 31, 2023	−11.6%

Inventory

Item	Latest	A year before	Change
Inventory, total	$1.1B⁹ Dec 31, 2025	$965.0M⁹ Dec 31, 2024	+10.5%
Work in process	$201.0M⁹ Dec 31, 2025	$190.0M⁹ Dec 31, 2024	+5.8%
Finished goods	$636.0M⁹ Dec 31, 2025	$539.0M⁹ Dec 31, 2024	+18.0%

Properties, in its own words

Solventum is a global organization with major centers throughout the world, including the license of the Company's U.S. principal office located at 3M Center in Maplewood, Minnesota from 3M Company. Additionally, the Company owns, leases or otherwise has rights to use a number of facilities, including administration, research and development, manufacturing, warehousing, distribution and other facilities across the United States and globally. The Company owns, leases or otherwise has rights to use approximately 270 facilities consisting of 20 owned facilities and approximately 250 facilities that are leased or otherwise have rights to use. The Company has 7 manufacturing facilities in the United States and 14 outside of the United States, including Canada, China, Germany, Ireland, Mexico, and Poland. Many of these facilities will serve more than one of our business segments and multiple functions across our business.

The Company's facilities are well-maintained and adequate for current needs. Solventum continues to evaluate its facility needs as the Company progresses on its journey as a separate company.

Item 2 of the 10-K filed Feb 27, 2026.¹³

The story

Spin-off

On July 26, 2022, 3M announced that it would spin off its healthcare division as a separate company to streamline operations. The new company would assume 3M's business in wound and oral care, health informatics, and biopharmaceutical filtration. The sales of products in these fields accounted for about a quarter of 3M's total sales in 2021. CEO Mike Roman said that the split would "position 3M for the future, to create more opportunity and greater certainty".

Bloomberg News noted that the move followed a period of declining profits attributed to shifting economic trends, and would "dramatically reshape a company known for diverse product lines, from electronic components to dental adhesives to Post-it notes". In fact, the announcement of the spin-off occurred the same day as a separate announcement that a 3M subsidiary, Aearo Technologies, had declared Chapter 11 bankruptcy after settling lawsuits alleging that the earplugs it had manufactured for U.S. military service members were defective and damaged their hearing.

Many observers placed this business decision in a larger trend of other industrial conglomerates that had undergone similar splits in the preceding few years. In November 2021, General Electric announced that it would spin off its health care, aerospace, and energy businesses as GE HealthCare, GE Aerospace, and GE Vernova, respectively; the same week, Johnson & Johnson announced that it would spin off its consumer health division as a separate company, Kenvue. Comparisons were also made to the decisions by Kellogg's and Toshiba to split into multiple entities, as well as United Technologies's spin-off of Otis Worldwide and Carrier Global before its merger with Raytheon. 3M itself sold its food safety business to Neogen in September 2022.

On January 24, 2023, the health care business was registered as a corporation in Delaware under the provisional name "3M Health Care Co.". On November 16, 2023, 3M unveiled that the new company would be called Solventum, a portmanteau of the words "solving" and "momentum".

The spin-off was completed on April 1, 2024, with 3M retaining about 19.9% of Solventum.

On February 25, 2025, it was announced that Thermo Fisher Scientific would acquire the company's Purification & Filtration business unit for $4.1B.

Independent operation

The first CEO of Solventum is Bryan Hanson, who has served in the role since September 1, 2023.

From Wikipedia’s article on Solventum, shared under CC BY-SA 4.0.⁷

Leadership

Who has led Solventum, and when. Pick a name to see everywhere that person has worked.

2025

Chief executive officerBryan C. Hanson Apr 2, 2024 to now¹⁴
ChairCarrie Cox¹
PresidentTeresa K. Crockett Mar 13, 2024 to Mar 13, 2024¹⁵
Chief financial officerWayde D. McMillan Apr 2, 2024 to now¹⁶

Board members and other officers (27)

SVP, Controller & CAONeil Zieselman Aug 18, 2026 to now¹⁷
Chief Commercial OfficerHeather Knight Nov 18, 2025 to now¹⁸
Vice PresidentMichael J. Ottesen Mar 13, 2024 to Mar 13, 2024¹⁹
TreasurerRodolfo Espinosa-Casaubon Mar 13, 2024 to Mar 13, 2024²⁰
Chief Information OfficerAmy Landucci Apr 2, 2024 to now²¹
Executive Vice PresidentChris Barry Apr 2, 2024 to now²²
Chief Accounting OfficerMary T. Wilcox Apr 2, 2024 to now²³
Chief Supply Chain OfficerPaul S. Harrington Apr 2, 2024 to now²⁴
Chief Human Resources OfficerTammy L. Gomez Apr 2, 2024 to now²⁵
Board memberJustin McGough Mar 13, 2024 to Mar 13, 2024²⁶
Board memberMichael J. Ottesen Mar 13, 2024 to Mar 13, 2024¹⁹
Board memberRodolfo Espinosa-Casaubon Mar 13, 2024 to Mar 13, 2024²⁰
Board memberTeresa K. Crockett Mar 13, 2024 to Mar 13, 2024¹⁵
Board memberTheresa E. Reinseth Mar 13, 2024 to Mar 13, 2024²⁷
Board memberAmy McBride Wendell Apr 2, 2024 to now²⁸
Board memberBernard A. Harris, Jr. Apr 2, 2024 to now²⁹
Board memberBryan C. Hanson Apr 2, 2024 to now¹⁴
Board memberCarlos Alban Apr 2, 2024 to now³⁰
Board memberCarrie Cox Apr 2, 2024 to now³¹
Board memberDarryl L. Wilson Apr 2, 2024 to now³²
Board memberElizabeth Mily Apr 2, 2024 to now³³
Board memberGlenn A. Eisenberg Apr 2, 2024 to now³⁴
Board memberJohn Weiland Apr 2, 2024 to now³⁵
Board memberKaren J. May Apr 2, 2024 to now³⁶
Board memberSusan DeVore Apr 2, 2024 to now³⁷
Board memberShirley Ann Edwards Apr 16, 2024 to now³⁸
General counselMarcela A. Kirberger Apr 2, 2024 to now³⁹

Products and brands

dental material
medical device
medical software

Listed on Wikidata.¹

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

3M Healthcare (Shanghai) Co. Ltd. China⁸
3M Healthcare Canada Company Limited Canada⁸
3M Healthcare EMEA Export Limited Ireland⁸
3M Medical Devices and Materials Manufacturing (Shanghai) Co., Ltd. China⁸
Crawford Healthcare Canada Limited Canada⁸
Crawford Healthcare Holdings Limited United Kingdom⁸
Crawford Healthcare Limited United Kingdom⁸
Derms Development Limited United Kingdom⁸
KCI APAC Holding Ltd Cayman Islands⁸
KCI Austria GmbH Austria⁸
KCI Brasil Importadora E Distribuidora De Produtos Para Saude Ltda. Brazil⁸
KCI Cayman Holdings Cayman Islands⁸
KCI Cayman Holdings II Cayman Islands⁸
KCI Clinic Spain, S.L.U. Spain⁸
KCI Colombia SAS Colombia⁸
KCI Europe Holding B.V. Netherlands⁸
KCI Hong Kong Holding Limited Hong Kong⁸
KCI KK Japan⁸
KCI MS Unlimited Cayman Islands⁸
KCI Manufacturing Unlimited Company Ireland⁸
KCI Medical (China) Co., Ltd. China⁸
KCI Medical AB Sweden⁸
KCI Medical AS Norway⁸
KCI Medical Aps Denmark⁸

All 85 listed subsidiaries

KCI Medical Asia Pte. Ltd. Singapore⁸
KCI Medical Australia Pty Ltd Australia⁸
KCI Medical B.V. Netherlands⁸
KCI Medical Belgium BVBA Belgium⁸
KCI Medical Canada Inc./ Fournitures Medicales KCI du Canada Inc. Canada⁸
KCI Medical GmbH Switzerland⁸
KCI Medical Holdings Unlimited Cayman Islands⁸
KCI Medical India Private limited India⁸
KCI Medical Limited Ireland⁸
KCI Medical Middle East & Africa FZ-LLC United Arab Emirates⁸
KCI Medical Middle East & Africa Trading L.L.C United Arab Emirates⁸
KCI Medical Puerto Rico, Inc. Puerto Rico⁸
KCI New Zealand Unlimited New Zealand⁸
KCI Polymedics BVBA Belgium⁸
KCI UK Holdings Limited United Kingdom⁸
KCI Wound Holdings Cayman Islands⁸
MModal Limited United Kingdom⁸
Medical Holdings Limited Malta⁸
SLVTM Portugal, Unipessoal Lda. Portugal⁸
Solventum (Thailand) Limited Thailand⁸
Solventum Arabia Medical Regional Headquarter Company One Person Saudi Arabia⁸
Solventum Arabia Trading Company (One Person) Saudi Arabia⁸
Solventum Chile SpA Chile⁸
Solventum Digital Science Community Limited Ireland⁸
Solventum Finland Oy Finland⁸
Solventum France SAS France⁸
Solventum GBS Poland sp. z o.o Poland⁸
Solventum GBS Sociedad de Responsabilidad Limitada Costa Rica⁸
Solventum Germany GmbH Germany⁸
Solventum Holdings B.V. Netherlands⁸
Solventum International Holdings Limited Ireland⁸
Solventum Investments (Shanghai) Co., Ltd. China⁸
Solventum Ireland Limited Ireland⁸
Solventum Italy S.R.L. Italy⁸
Solventum Japan GK Japan⁸
Solventum Japan Holdings G.K. Japan⁸
Solventum Japan Innovation Limited Japan⁸
Solventum Japan Products Limited Japan⁸
Solventum Malaysia Sdn. Bhd. Malaysia⁸
Solventum Material Technology (Guangzhou) Co., Ltd. China⁸
Solventum Mexico S. de R.L. de C.V. Mexico⁸
Solventum México Manufacturing, S. de R.L. de C.V. Mexico⁸
Solventum Operational Real Estate GmbH & Co. KG Germany⁸
Solventum Operations Pty. Ltd. Australia⁸
Solventum Poland Manufacturing Sp. z o.o Poland⁸
Solventum Poland sp. z o.o Poland⁸
Solventum Purification, S. de R.L. de C.V. Mexico⁸
Solventum Real Estate GP GmbH Germany⁸
Solventum Real Estate GmbH Germany⁸
Solventum Taiwan Co. Ltd Taiwan⁸
Solventum Technologies Israel Ltd. Israel⁸
Solventum Turkey Sağlık Ürünleri ve Tıbbi Cihaz İthalat ve Ticaret Limited Şirketi Turkey⁸
Solventum UK Holding Company Ltd United Kingdom⁸
Solventum Vietnam LLC Vietnam⁸
Solventum do Brasil Ltda. Brazil⁸
Solvers Insurance Group Limited Bermuda⁸
Systagenix Wound Management (South Africa) (Proprietary) Limited South Africa⁸
Systagenix Wound Management B.V. Netherlands⁸
Systagenix Wound Management Mezz B.V. Netherlands⁸
Systagenix Wound Management, Limited United Kingdom⁸
Trimodal Softech Solutions Private Limited India⁸

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Employees over time

202520,000¹
202422,000¹

Former names

3M Health Care CoFeb 14, 2023 to Feb 9, 2024⁶
3M Health Care CompanyJan 24, 2023 to Feb 2024¹

Timeline

Aug 5, 20268-K Regulation FD disclosure; Other events⁴⁰
Aug 5, 20268-K Results of operations⁴¹
Jul 20, 20268-K Executive or director change⁴²
Jun 5, 20268-K Other events⁴³
May 27, 20268-K Executive or director change⁴⁴
May 20, 20268-K Shareholder vote⁴⁵
May 5, 20268-K Results of operations⁴⁶
Mar 24, 20268-K Executive or director change⁴⁷
Feb 26, 20268-K Results of operations⁴⁸
Dec 16, 20258-K Regulation FD disclosure⁴⁹
Nov 6, 20258-K Results of operations⁵⁰
Oct 21, 20258-K Executive or director change⁵¹
Apr 2, 2024New chief executive Bryan C. Hanson becomes CEO¹⁴
Apr 1, 2024Went public Listed on NYSE¹
Apr 1, 2024Founded Founded in Delaware¹

Calendar

Coming up

Nov 5, 2026 · After the closeReports results for the quarter ending Sep/2026 A year earlier it reported $1.50 a share, on Nov 6, 2025.⁵²

When it reported results

Aug 5, 2026Reported quarterly or annual results⁴¹
May 5, 2026Reported quarterly or annual results⁴⁶
Feb 26, 2026Reported quarterly or annual results⁴⁸
Nov 6, 2025Reported quarterly or annual results⁵⁰
Aug 7, 2025Reported quarterly or annual results⁵³
May 8, 2025Reported quarterly or annual results⁵⁴
Feb 27, 2025Reported quarterly or annual results⁵⁵
Nov 7, 2024Reported quarterly or annual results⁵⁶

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

261 filings to the SEC since October 2021: 2 annual reports, 8 quarterly reports, 32 major events, 153 insider forms, 11 large holders, 55 other. The latest 20:

Sep 3, 20264 EDGAR
Aug 18, 20263 EDGAR
Aug 18, 20264 EDGAR
Aug 5, 202610-Q EDGAR
Aug 5, 20268-K EDGAR
Aug 5, 20268-K EDGAR
Jul 20, 20268-K EDGAR
Jun 5, 20268-K EDGAR
May 29, 2026SD EDGAR
May 27, 20268-K EDGAR
May 20, 20268-K EDGAR
May 18, 20264 EDGAR
May 18, 20264 EDGAR
May 18, 20264 EDGAR
May 18, 20264 EDGAR
May 18, 20264 EDGAR
May 18, 20264 EDGAR
May 18, 20264 EDGAR
May 18, 20264 EDGAR
May 18, 20264 EDGAR

The 261 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 1 buys and 1 sales. Grants, option exercises and gifts are left out.

Date	Who	Trade	Shares	Price	Value	Filing
Mar 10, 2026	Wendell Amy McBrideDirector	Buy	1,475	$68.03	$100.3K	Form 4
Aug 15, 2025	3M CO10% owner	Sale	8,800,000	$73.45	$646.4M	Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 30, 2026⁵⁷
VANGUARD GROUP INCSCHEDULE 13G/A, 3 filings Nov 4, 2024 to Mar 27, 2026⁵⁸
Independent Franchise Partners LLPSCHEDULE 13G/A, 3 filings Aug 13, 2025 to Jan 27, 2026⁵⁹
3MSCHEDULE 13G/A, 2 filings Nov 14, 2024 to Aug 18, 2025⁶⁰
BlackRockSC 13G, 2 filings Oct 24, 2024 to Nov 8, 2024⁶¹

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Year	Executive	Salary	Total pay
2025	Bryan C. HansonChief Executive Officer	$1.4M	$20.1M⁶²
2025	Heather KnightChief Commercial Officer	$112.8K	$7.9M⁶²
2025	Wayde D. McMillanChief Financial Officer	$773.2K	$6.2M⁶²
2025	Christopher BarryFormer EVP and Group President, Medical Surgical	$996.8K	$4.2M⁶²
2025	Marcela A. KirbergerChief Corporate & Legal Officer	$728.7K	$3.6M⁶²
2025	Amy L. LanducciChief Information & Digital Officer	$684.9K	$3.5M⁶²
2024	Bryan C. HansonChief Executive Officer	$1.4M	$40.0M⁶²
2024	Wayde D. McMillanChief Financial Officer	$753.4K	$10.3M⁶²
2024	Christopher BarryFormer EVP and Group President, Medical Surgical	$812.5K	$9.8M⁶²
2024	Amy L. LanducciChief Information & Digital Officer	$664.6K	$9.1M⁶²

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Independent Franchise Partners LLP	16,170,038	$1.2B	8.2%	+436,543
BlackRock, Inc.	9,761,863	$753.1M	0.0%	−717,109
Vanguard Capital Management LLC	9,624,829	$742.6M	0.0%	+22,880
Trian Fund Management, L.P.	8,236,753	$635.5M	15.0%	No change
Vanguard Portfolio Management LLC	6,328,641	$488.3M	0.0%	−61,723
Davis Selected Advisers	6,307,729	$486.7M	2.1%	−22,596
State Street Corp	5,639,230	$435.1M	0.0%	−768,250
Geode Capital Management, LLC	4,910,624	$378.3M	0.0%	+158,364
Boston Partners	4,037,963	$311.5M	0.3%	+123,872
Invesco Ltd.	3,309,915	$255.4M	0.0%	−479,968
Fmr LLC	2,079,141	$160.4M	0.0%	+209,105
State Farm Mutual Automobile Insurance Co	2,069,279	$159.6M	0.1%	No change
Diamond Hill Capital Management, LLC (Investment Advisor)	1,945,121	$150.1M	1.2%	−475,125
Dimensional Fund Advisors LP	1,817,658	$140.2M	0.0%	+1,042,975
Madison Avenue Partners, LP	1,741,221	$134.3M	5.8%	−134,515
Norges Bank	1,713,676	$132.2M	0.0%	New
Morgan Stanley	1,533,215	$118.3M	0.0%	−229,792
Charles Schwab Investment Management Inc	1,522,657	$117.5M	0.0%	+3,143
Northern Trust Corp	1,387,579	$107.1M	0.0%	−151,826
Bank Of America Corp /de/	1,291,866	$99.7M	0.0%	−140,914
Millennium Management LLC	1,199,940	$92.6M	0.1%	+659,647
Aqr Capital Management LLC	1,082,100	$83.5M	0.0%	+352,055
Goldman Sachs Group Inc	956,447	$73.8M	0.0%	+135,415
Polar Capital Holdings Plc	935,761	$72.2M	0.2%	New
Raymond James Financial Inc	900,421	$69.5M	0.0%	−18,842

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

7 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

Date	Member	Trade	Amount	Vs S&P since	Filing
Mar 27, 2026	Alan ArmstrongRepublican, Senate	Buy	$1,001 - $15,000	+18.2%	Report
Dec 31, 2025	J. French HillRepublican, House	Sale	$15,001 - $50,000	+2.3%	Report
Feb 6, 2025	Ron WydenDemocratic, Senate	Sale	$1,001 - $15,000	+9.8%	Report
Jan 15, 2025	Julie JohnsonDemocratic, House	Sale	$1,001 - $15,000	+8.2%	Report
May 14, 2024	Gary C. PetersDemocratic, Senate	Sale	$1,001 - $15,000	+12.6%	Report
May 3, 2024	Tommy TubervilleRepublican, Senate	Buy	$1,001 - $15,000	−15.1%	Report
May 3, 2024	Tommy TubervilleRepublican, Senate	Sale	$1,001 - $15,000	+15.1%	Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Solventum is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARSolventum Corp²
CIK0001964738
Employer ID (EIN)92-2008841¹³
Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company¹³
Incorporated inDelaware¹³
Fiscal year endsDecember 31²
Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus²
SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance²
Business address1750 Yankee Doodle Road, Eagan, MN 55121²
Phone651-733-1110²
Shares outstanding170,223,729 as of Jul 31, 2026¹²
Public float$13.1B as of Jun 30, 2025¹³
AuditorPricewaterhouseCoopers LLP, Minneapolis, Minnesota PCAOB ID 238; no auditor attestation of internal control over financial reporting¹³
On EDGAR sinceFeb 14, 2023²
Filings261 in all: 4 (125), 8-K (32), 3 (27), UPLOAD (9), 10-Q (8), DRS/A (7), DRSLTR (6), CORRESP (5)²
All 33 form types
SCHEDULE 13G/A (4), IRANNOTICE (3), SCHEDULE 13G (3), 10-12B/A (2), 10-K (2), 424B7 (2), DEF 14A (2), DEFA14A (2), EFFECT (2), SC 13G (2), SC 13G/A (2), SD (2), SEC STAFF LETTER (2), 10-12B (1), 4/A (1), 424B3 (1), ARS (1), CERT (1), DRS (1), FWP (1), POS AM (1), S-3ASR (1), S-4 (1), S-8 (1), SEC STAFF ACTION (1)
Latest filingsAnnual report (10-K) Feb 27, 2026
Quarterly report (10-Q) Aug 5, 2026
Proxy statement (DEF 14A) Mar 27, 2026
Latest 8-K (8-K) Aug 5, 2026

Securities registered for trading

Class	Symbol	Exchange
Common Stock, Par Value $0.01 Per Share	SOLV	New York Stock Exchange

From the cover page of the 10-K filed Feb 27, 2026 (Section 12(b) of the Exchange Act).¹³

Risk factors and legal proceedings

The risks Solventum names in Item 1A of its 10-K filed Feb 27, 2026: 40 risks under these headings, as written.¹³

Risks Related to the Spin-Off and Solventum’s Relationship with 3M
Solventum’s historical financial information for periods prior to the Spin-Off is not necessarily representative of the results or performance that it would have achieved as a separate, publicly traded company and may not be a reliable indicator of its future results or performance.
Solventum may not achieve some or all of the expected benefits of the Spin-Off.
Solventum’s accounting and other management systems and resources may not be adequately prepared to meet the financial reporting and other requirements to which it is subject to as a standalone publicly traded company following the Spin-Off.
In connection with the Spin-Off, Solventum incurred debt obligations and may incur additional obligations in the future, which could adversely affect its business and profitability and its ability to meet other obligations.
Solventum may not be able to engage in desirable capital-raising or strategic transactions following the Spin-Off.
The transfer to Solventum of certain contracts, permits and other assets and rights may have required the consents or approvals of, or provide other rights to, third parties and governmental authorities. If such consents or approvals were not
obtained, Solventum may not be entitled to the full benefit of such contracts, permits and other assets and rights, which could increase its expenses or otherwise harm its business and financial performance.
Following the Spin-Off, Solventum’s commercial relationships with 3M remain significant, which could adversely affect Solventum’s business, its ability to meet other obligations and the market price of its common stock.
Risks Related to Solventum’s Business
General Economic and Business Risks
Solventum’s results may be impacted by the effects of, and changes in, worldwide economic, political, regulatory, international trade and geopolitical conditions, war and other events beyond its control.

The other 31 risks

The deployment and use of artificial intelligence ("AI"), machine learning, or other emerging technologies in Solventum’s products and services, including as part of its research and development efforts, or its failure to adapt its products or services to industry trends and developments related to such technologies in a timely manner, or at all, could adversely affect Solventum’s business, financial condition, results of operations and cash flows.
Public health crises may increase Solventum’s cost of doing business and disrupt Solventum’s operations.
Our brands are critical to our success, and damage to our reputation or our brands could adversely affect our business, results of operations or financial condition.
Acquisitions, strategic alliances, divestitures and other strategic events resulting from portfolio management actions and other evolving business strategies, and possible further organizational restructuring, could affect future results.
Solventum may not be able to effectively integrate acquired businesses into its operations or achieve expected cost savings or profitability from its acquisitions.
Solventum’s restructuring program may not be successful or Solventum may not fully realize the expected cost savings and/or operating efficiencies from its restructuring initiatives.
Solventum may not be able to access the capital and credit markets on terms that are favorable to Solventum, or at all.
Change in Solventum’s credit ratings could increase cost of funding.
Foreign currency exchange rates and fluctuations in those rates may affect Solventum’s ability to realize projected growth rates in its sales and earnings.
Changes in interest rates could adversely affect Solventum.
Market Dynamic Risks
Solventum operates in highly competitive markets, competition may increase in the future and the healthcare industry may be disrupted, necessitating that Solventum lower prices or resulting in a loss of market share.
Consolidation in the healthcare industry could have an adverse effect on Solventum’s revenues and results of operations.
Reductions in customers’ research budgets or government funding may adversely affect Solventum’s business.
Solventum’s growth objectives are largely dependent on the timing and market acceptance of its new products and services, including its ability to continually renew its pipeline of new products and services and to bring those products and services to market.
The success of many of Solventum’s products depends upon certain key healthcare professionals.
Changes in reimbursement practices of third-party payers or other cost containment measures or worsening economic conditions could affect the demand for Solventum’s products and the prices at which they are sold.
Solventum’s future results are subject to vulnerability with respect to materials and fluctuations in the costs and availability of purchased components, compounds, raw materials, energy, production capacity and labor due to shortages, increased demand and wages, logistics, supply chain interruptions, manufacturing site disruptions, regulatory developments, tariffs, inflation and other disruptive factors.
3M is the sole source of supply for raw materials used in certain of our products and our business will be harmed if 3M does not satisfy our requirements.
Legal and Compliance Risks
Solventum may face potential liabilities related to PFAS, which could adversely impact Solventum’s results.
Climate change and the impacts of climate change may materially adversely affect Solventum’s business, results of operations, financial condition and cash flows.
Solventum operates in a strictly regulated industry, and compliance with laws and regulations applicable to the commercialization of Solventum’s products is costly and failure to comply may result in significant penalties.
Solventum is subject to laws and regulations governing government contracts, public procurement and government reimbursements in many jurisdictions, as to which the failure to comply could adversely affect Solventum’s business.
Solventum is exposed to risks associated with product liability claims, including existing claims and claims resulting from the actions or inactions of its customers or third parties, and product recalls or safety alerts that are outside of its control.
Information Technology and Intellectual Property Risks
Solventum may be unable to obtain, maintain, protect or effectively enforce its intellectual property rights.
Tax Matters Risks
Changes in tax rates, laws or regulations could adversely impact Solventum’s financial results.
Solventum’s tax burden could increase as a result of ongoing or future tax audits and inquiries.
Solventum could be negatively impacted by future changes in the allocation of income to each of the income tax jurisdictions in which Solventum operates.
Employee Matters Risks
If Solventum is unable to attract or retain key personnel and qualified employees, or maintain relations with its employees, unions and other employee representatives, Solventum’s business would be adversely affected.
Risks Related to Solventum Common Stock
A significant number of shares of Solventum common stock may be sold by 3M or others, which may cause the Solventum stock price to decline.
Because Solventum does not currently intend to pay any dividends on its common stock, holders of its common stock must rely on stock appreciation for any return on their investment. Solventum cannot guarantee the timing, declaration, amount or payment of dividends on its common stock.
Anti-takeover provisions could enable Solventum’s Board of Directors to resist a takeover attempt by a third party and limit the power of its shareholders.

Legal proceedings

Discussion of legal matters is incorporated by reference from Part II, Item 8, Note 12, "Commitments and Contingencies," to the consolidated financial statements, and should be considered an integral part of Part I, Item 3, "Legal Proceedings."

The opening of Item 3, Legal Proceedings.¹³

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataSolventum on Wikidata
2
SEC EDGARSolventum filings on SEC EDGAR
3
WikipediaSolventum on Wikipedia
4
GLEIFSolventum LEI record (254900I70403OSGY4M28)
5
Wikimedia CommonsSolventum logo by Solventum, Public domain
6
SEC EDGARSolventum filings on SEC EDGAR
7
WikipediaSolventum on Wikipedia (revision used)
8
SEC EDGARSolventum annual report, Exhibit 21 (subsidiaries)
9
SEC EDGARSolventum 10-K for fiscal 2025
10
SEC EDGARSolventum 10-K for fiscal 2022
11
SEC EDGARSolventum 10-Q for fiscal 2026
12
SEC EDGARSolventum 10-Q for fiscal 2026
13
SEC EDGARSolventum 10-K filed Feb 27, 2026: Item 2, Properties
14
SEC EDGARBryan C. Hanson, Chief executive officer
15
SEC EDGARTeresa K. Crockett, President
16
SEC EDGARWayde D. McMillan, Chief financial officer
17
SEC EDGARNeil Zieselman, SVP, Controller & CAO
18
SEC EDGARHeather Knight, Chief Commercial Officer
19
SEC EDGARMichael J. Ottesen, Vice President
20
SEC EDGARRodolfo Espinosa-Casaubon, Treasurer
21
SEC EDGARAmy Landucci, Chief Information Officer
22
SEC EDGARChris Barry, Executive Vice President
23
SEC EDGARMary T. Wilcox, Chief Accounting Officer
24
SEC EDGARPaul S. Harrington, Chief Supply Chain Officer
25
SEC EDGARTammy L. Gomez, Chief Human Resources Officer
26
SEC EDGARJustin McGough, Board member
27
SEC EDGARTheresa E. Reinseth, Board member
28
SEC EDGARAmy McBride Wendell, Board member
29
SEC EDGARBernard A. Harris, Jr., Board member
30
SEC EDGARCarlos Alban, Board member
31
SEC EDGARCarrie Cox, Board member
32
SEC EDGARDarryl L. Wilson, Board member
33
SEC EDGARElizabeth Mily, Board member
34
SEC EDGARGlenn A. Eisenberg, Board member
35
SEC EDGARJohn Weiland, Board member
36
SEC EDGARKaren J. May, Board member
37
SEC EDGARSusan DeVore, Board member
38
SEC EDGARShirley Ann Edwards, Board member
39
SEC EDGARMarcela A. Kirberger, General counsel
40
SEC EDGARRegulation FD disclosure; Other events
41
SEC EDGARResults of operations
42
SEC EDGARExecutive or director change
43
SEC EDGAROther events
44
SEC EDGARExecutive or director change
45
SEC EDGARShareholder vote
46
SEC EDGARResults of operations
47
SEC EDGARExecutive or director change
48
SEC EDGARResults of operations
49
SEC EDGARRegulation FD disclosure
50
SEC EDGARResults of operations
51
SEC EDGARExecutive or director change
52
NasdaqNasdaq calendar
53
SEC EDGARSolventum 8-K, Item 2.02 (results of operations)
54
SEC EDGARSolventum 8-K, Item 2.02 (results of operations)
55
SEC EDGARSolventum 8-K, Item 2.02 (results of operations)
56
SEC EDGARSolventum 8-K, Item 2.02 (results of operations)
57
SEC EDGARVANGUARD CAPITAL MANAGEMENT LLC SCHEDULE 13G on Solventum
58
SEC EDGARVANGUARD GROUP INC SCHEDULE 13G/A on Solventum
59
SEC EDGARIndependent Franchise Partners LLP SCHEDULE 13G/A on Solventum
60
SEC EDGAR3M SCHEDULE 13G/A on Solventum
61
SEC EDGARBlackRock SC 13G on Solventum
62
SEC EDGARSolventum proxy statement (DEF 14A), 2025 pay